ReviewHematology. American Society of Hematology. Education Program2018
Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura.
Review in Hematology. American Society of Hematology. Education Program, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 59 citations in OpenAlex.
- Fatal interplay between acquired thrombotic thrombocytopenic purpura and posterior reversible encephalopathy syndrome: a case report.Radiology case reports · 2025Article
- Beyond the Limits of Conventional Coagulation Tests: A Comprehensive Overview of ACLF-Related Coagulopathies.Journal of clinical medicine · 2025Review
- Recurrent Multi-territorial Ischemic Stroke As the Initial Presentation of Thrombotic Thrombocytopenic Purpura.Cureus · 2025Article
- ADAMTS13 in the New Era of TTP.International journal of molecular sciences · 2024Review
- A case of acquired thrombotic thrombocytopenic purpura following near-drowning.Clinical nephrology. Case studies · 2024Article
- Co-Occurring Thrombotic Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia in a Child Carrying the Pathogenic SHOC2 c.4A>G (p.Ser2Gly) Variant.The American journal of case reports · 2023Article
- Changes in inflammatory responses and autophagy during apheresis platelet preservation and their correlation with platelet transfusion refractoriness in patients with acute lymphoblastic leukemia.Biomolecules & biomedicine · 2023Article
- Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition.BMC nephrology · 2023Article
- Immune thrombotic thrombocytopenic purpura: Spotlight on long-term outcomes and survivorship.Frontiers in medicine · 2023Review
- Therapeutic apheresis in kidney diseases: an updated review.Renal failure · 2022Review
- Coronavirus Disease 2019-Associated Thrombotic Microangiopathy: Literature Review.International journal of molecular sciences · 2022Review
- Coronavirus Disease 2019-Associated Thrombotic Microangiopathy.Journal of hematology · 2022Article
- Application of PLASMIC Score in Risk Prediction of Thrombotic Thrombocytopenic Purpura: Real-World Experience From a Tertiary Medical Center in Taiwan.Frontiers in medicine · 2022Article
- COVID-19 and thrombotic microangiopathies.Thrombosis research · 2021Review
- Article
- Case Report: Two Cases of Pediatric Thrombotic Thrombocytopenic Purpura Treated With Combined Therapy.Frontiers in pediatrics · 2021Article
- Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions.Therapeutics and clinical risk management · 2021Review
- Reduced sensitivity of PLASMIC and French scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals.Transfusion · 2021Article
- Blood substitution therapy rescues the brain of mice from ischemic damage.Nature communications · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of plasma exchange has dramatically changed the prognosis of acute thrombotic thrombocytopenic purpura (TTP). Recent insights into TTP pathogenesis have led to the development of novel therapies targeting pathogenic anti-ADAMTS13 antibody production, von Willebrand factor (VWF)-platelet interactions, and ADAMTS13 replacement. Retrospective and prospective studies have established the efficacy of rituximab as an adjunct to plasma exchange for patients with acute TTP, either upfront or for refractory disease. Relapse prevention is a major concern for survivors of acute TTP, and emerging data support the prophylactic use of rituximab in patients with persistent or recurrent ADAMTS13 deficiency in clinical remission. Capalcizumab, a nanobody directed against domain A1 of VWF that prevents the formation of VWF-platelet aggregates, recently completed phase 2 (TITAN) and 3 (HERCULES) trials with encouraging results. Compared with placebo, caplacizumab shortened the time to platelet recovery and may protect against microthrombotic tissue injury in the acute phase of TTP, though it does not modify the underlying immune response. Other promising therapies including plasma cell inhibitors (bortezomib), recombinant ADAMTS13,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.